Directors’ Trades: These ASX directors went a-share buying as part of their Christmas shopping
Link copied to
The fortnight prior to Christmas saw over 30 ASX company directors make trades in their company’s shares of $100,000 or more – most of them buys.
Four buys and one sale were above $1 million. The sale came from outgoing Medical Developments International (ASX:MVP) chairman David Williams who sold off market to his successor Gordon Naylor – a former CSL (ASX:CSL) executive.
Altech Chemicals’ (ASX:ATC) Tunku Yaacob Kyrra took the cake, investing $2.6 million in his company’s rights issue.
Rounding out the list was Kevin Perkins hailing from restaurant owner Collins Foods (ASX:CKF). He bought just over $1 million on market.
Among the other buys was Priyank Thapliyal from Jupiter Mines (ASX:JMS) who bought $545,000 on market – just a month after his colleague Brian Gilbertson bought $2.7 million.
Still on resources and Sihayo Gold (ASX:SIH) Gavin Caudle bought $500,000 in his company’s placement while James Askew, chairman of one of the ASX’s larger graphite stocks in Syrah Resources (ASX:SYR), bought just over $100,000 on market.
Daniel Foggo and Susan Forrester from fintech lender Plenti (ASX:PLT) bought $131,891 and $205,128 of shares respectively, despite their company being one of the few IPOs not to do well in 2020.
Eric Wang from Ecofibre (ASX:EOF), one of the largest cannabis stocks and one of the few in hemp, bought $745,183 on market.
Moving on to sales made in ASX shares by company directors just before Christmas, the next largest – after David Williams’ $1m+ trade – was Brendon Cook from oOh!media (ASX:OML) who sold just over $800,000 in shares.
Cook’s company was heavily hit by companies cutting expenditure on advertising but it told shareholders earlier this month things were looking up as consumers exited lockdowns.
Cook founded the company in 1989 and began this year by announcing he was stepping back.
He then opted to delay this during COVID-19 but in September announced he’d be handing the reigns to former Nova CEO Cathy O’Connor next year.
Next was Axel Hoos of Sydney biotech company Imugene (ASX:IMU) who parted with $345,300 in shares.